Koers Vertex Pharmaceuticals Incorporated
Aandelen
VRTX
US92532F1003
Biotechnologie & Medisch Onderzoek
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
397,5 USD | -0,06% | +0,81% | -2,31% |
Omzet 2024 * | 10,72 mld. 10,03 mld. | Omzet 2025 * | 11,74 mld. 10,98 mld. | Marktkapitalisatie | 103 mld. 96,08 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 3,86 mld. 3,61 mld. | Nettowinst (verlies) 2025 * | 4,44 mld. 4,16 mld. | EV/omzet 2024 * | 8 x |
Nettoliquiditeiten 2024 * | 16,91 mld. 15,82 mld. | Nettoliquiditeiten 2025 * | 21,28 mld. 19,9 mld. | EV/omzet 2025 * | 6,94 x |
K/w-verhouding 2024 * |
26,7
x | K/w-verhouding 2025 * |
23,2
x | Werknemers | 5.400 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 99,89% |
Recentste transcriptie over Vertex Pharmaceuticals Incorporated
1 dag | -0,06% | ||
1 week | +0,81% | ||
Lopende maand | -4,91% | ||
1 maand | -5,01% | ||
3 maanden | -7,60% | ||
6 maanden | +10,02% | ||
Lopend jaar | -2,31% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 51 | 01-02-17 | |
Jeffrey Leiden
CHM | Chairman | 68 | 08-07-09 |
Charles Wagner
DFI | Director of Finance/CFO | 55 | 10-04-19 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Alan Garber
BRD | Director/Board Member | 68 | 08-06-17 |
Jeffrey Leiden
CHM | Chairman | 68 | 08-07-09 |
Bruce Sachs
BRD | Director/Board Member | 64 | 01-01-98 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
7.67% | 0 M€ | 0,00% | - | |
7.08% | 0 M€ | 0,00% | - |
Datum | Koers | Variatie | Volume |
---|---|---|---|
26-04-24 | 397,5 | -0,06% | 682 467 |
25-04-24 | 397,7 | -0,76% | 787 700 |
24-04-24 | 400,8 | -1,02% | 806 473 |
23-04-24 | 404,9 | +1,25% | 1 070 343 |
22-04-24 | 399,9 | +1,43% | 1 393 886 |
uitgestelde koers Nasdaq, 26 april 2024 om 22:00 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-2,31% | 103 mld. | |
+0,56% | 95,71 mld. | |
+1,69% | 22,02 mld. | |
-17,37% | 20,9 mld. | |
-9,30% | 17,85 mld. | |
-41,01% | 16,21 mld. | |
-14,85% | 15,52 mld. | |
+3,21% | 13,86 mld. | |
+33,54% | 12,04 mld. | |
-24,71% | 8,08 mld. |